Findings

What do systematic reviews say?

2,293 questions · 2,395 findings · 172 reviews · Gut

Sort:Best matchNewestHighest certainty Download CSV

No studies found 420 · 17.5%GRADE not reported 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%

Intervention not reported

Health‐related quality of life · people with acute pancreatitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for acute pancreatitis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

On‐demand deprescribing vs continued use

Lack of symptom control · people with moderate GERD and mild esophagitis, mean age 48 to 57 years

On‐demand deprescribing may leads to higher lack of symptom control compared with continued use (low certainty).

1 finding from 1 review

Deprescribing versus continuation of chronic proton pump inhibitor use in adults 2017 · Cochrane Headline outcomes only
RR 1.71 [1.31, 2.21]
5 studies · 1653 participants
Low

On‐demand deprescribing vs continued use

Pill use (pills/week) · people with moderate GERD and mild esophagitis, mean age 48 to 57 years

1 finding from 1 review

Deprescribing versus continuation of chronic proton pump inhibitor use in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1152 participants
Moderate

On‐demand deprescribing vs continued use

Use of healthcare resources (cost effectiveness, time taken to fit, number of dental visits) · people with moderate GERD and mild esophagitis, mean age 48 to 57 years

The review found no eligible studies for this question.

1 finding from 1 review

Deprescribing versus continuation of chronic proton pump inhibitor use in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

On‐demand deprescribing vs continued use

Adverse drug withdrawal events ‐ esophagitis (endoscopic findings) · people with moderate GERD and mild esophagitis, mean age 48 to 57 years

On‐demand deprescribing may leads to higher adverse drug withdrawal events ‐ esophagitis (endoscopic findings) compared with continued use (low certainty).

1 finding from 1 review

Deprescribing versus continuation of chronic proton pump inhibitor use in adults 2017 · Cochrane Headline outcomes only
RR 30.59 [1.84, 508.91]
1 study · 598 participants
Low

On‐demand deprescribing vs continued use

Participant satisfaction · people with moderate GERD and mild esophagitis, mean age 48 to 57 years

It is very uncertain whether on‐demand deprescribing changes participant satisfaction compared with continued use (very low certainty).

1 finding from 1 review

Deprescribing versus continuation of chronic proton pump inhibitor use in adults 2017 · Cochrane Headline outcomes only
RR 1.82 [1.26, 2.65]
5 studies · 1653 participants
Very low

Abrupt discontinuation deprescribing vs continued use

Lack of symptom control · people with mild to moderate esophagitis, symptomatic, aged > 18 years (mean age 73 years)

It is very uncertain whether abrupt discontinuation deprescribing changes lack of symptom control compared with continued use (very low certainty).

1 finding from 1 review

Deprescribing versus continuation of chronic proton pump inhibitor use in adults 2017 · Cochrane Headline outcomes only
RR 3.02 [1.74, 5.24]
1 study · 105 participants
Very low

Abrupt discontinuation deprescribing vs continued use

Adverse drug withdrawal events ‐ relapse (endoscopic findings) · people with mild to moderate esophagitis, symptomatic, aged > 18 years (mean age 73 years)

It is very uncertain whether abrupt discontinuation deprescribing changes adverse drug withdrawal events ‐ relapse (endoscopic findings) compared with continued use (very low certainty).

1 finding from 1 review

Deprescribing versus continuation of chronic proton pump inhibitor use in adults 2017 · Cochrane Headline outcomes only
RR 3.41 [1.91, 6.09]
1 study · 105 participants
Very low

Pancreaticojejunostomy vs pancreatogastrostomy after pancreatoduodectomy

Postoperative pancreatic fistula (Grade A, B or C) · adults undergoing pancreatoduodenectomy (mainly for pancreatic cancer)

Pancreaticojejunostomy showed no clear difference in postoperative pancreatic fistula (Grade A, B or C) compared with pancreatogastrostomy after pancreatoduodectomy (low certainty).

1 finding from 1 review

Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic… 2017 · Cochrane Headline outcomes only
RR 1.19 [0.88, 1.62]
9 studies · 1513 participants
Low

Pancreaticojejunostomy vs pancreatogastrostomy after pancreatoduodectomy

Cost analysis · adults undergoing pancreatoduodenectomy (mainly for pancreatic cancer)

The review found no eligible studies for this question.

1 finding from 1 review

Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pancreaticojejunostomy vs pancreatogastrostomy after pancreatoduodectomy

Postoperative pancreatic fistula (grade B or C) · adults undergoing pancreatoduodenectomy (mainly for pancreatic cancer)

It is very uncertain whether pancreaticojejunostomy changes clinically significant pancreatic fistula (Grade B or C) compared with pancreatogastrostomy after pancreatoduodectomy (very low certainty).

1 finding from 1 review

Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic… 2017 · Cochrane Headline outcomes only
RR 1.51 [0.92, 2.47]
7 studies · 1184 participants
Very low

Pancreaticojejunostomy vs pancreatogastrostomy after pancreatoduodectomy

Postoperative mortality · adults undergoing pancreatoduodenectomy (mainly for pancreatic cancer)

Pancreaticojejunostomy showed no clear difference in postoperative mortality compared with pancreatogastrostomy after pancreatoduodectomy (moderate certainty).

1 finding from 1 review

Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic… 2017 · Cochrane Headline outcomes only
RR 0.84 [0.53, 1.34]
10 studies · 1629 participants
Moderate

Pancreaticojejunostomy vs pancreatogastrostomy after pancreatoduodectomy

Length of hospital stay · adults undergoing pancreatoduodenectomy (mainly for pancreatic cancer)

Pancreaticojejunostomy showed no clear difference in length of hospital stay compared with pancreatogastrostomy after pancreatoduodectomy (low certainty).

1 finding from 1 review

Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic… 2017 · Cochrane Headline outcomes only
MD 1.04
4 studies · 502 participants
Low

Pancreaticojejunostomy vs pancreatogastrostomy after pancreatoduodectomy

Rate of surgical re‐intervention: TEG or ROTEM vs control · adults undergoing pancreatoduodenectomy (mainly for pancreatic cancer)

Pancreaticojejunostomy showed no clear difference in surgical re‐intervention compared with pancreatogastrostomy after pancreatoduodectomy (low certainty).

1 finding from 1 review

Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic… 2017 · Cochrane Headline outcomes only
RR 1.18 [0.86, 1.61]
7 studies · 1263 participants
Low

Pancreaticojejunostomy vs pancreatogastrostomy after pancreatoduodectomy

Overall rate of surgical complications · adults undergoing pancreatoduodenectomy (mainly for pancreatic cancer)

Pancreaticojejunostomy showed no clear difference in surgical complications compared with pancreatogastrostomy after pancreatoduodectomy (moderate certainty).

1 finding from 1 review

Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic… 2017 · Cochrane Headline outcomes only
RR 1.03 [0.9, 1.18]
9 studies · 1513 participants
Moderate

Pancreaticojejunostomy vs pancreatogastrostomy after pancreatoduodectomy

Postoperative bleeding · adults undergoing pancreatoduodenectomy (mainly for pancreatic cancer)

Pancreaticojejunostomy may leads to lower postoperative bleeding compared with pancreatogastrostomy after pancreatoduodectomy (low certainty).

1 finding from 1 review

Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic… 2017 · Cochrane Headline outcomes only
RR 0.69 [0.51, 0.93]
8 studies · 1386 participants
Low

Pancreaticojejunostomy vs pancreatogastrostomy after pancreatoduodectomy

Intra‐abdominal abscess · adults undergoing pancreatoduodenectomy (mainly for pancreatic cancer)

Pancreaticojejunostomy may leads to higher intra‐abdominal abscess compared with pancreatogastrostomy after pancreatoduodectomy (low certainty).

1 finding from 1 review

Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic… 2017 · Cochrane Headline outcomes only
RR 1.77 [1.11, 2.81]
7 studies · 1121 participants
Low

Pancreaticojejunostomy vs pancreatogastrostomy after pancreatoduodectomy

Quality of life · adults undergoing pancreatoduodenectomy (mainly for pancreatic cancer)

1 finding from 1 review

Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 320 participants
Low

Anti‐TB therapy vs placebo

Relapse · maintenance of remission in Crohn's disease

It is very uncertain whether anti‐TB therapy changes relapse compared with placebo (very low certainty).

1 finding from 1 review

Anti‐tuberculous therapy for maintenance of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.58 [0.45, 0.75]
4 studies · 206 participants
Very low

Anti‐TB therapy vs placebo

Adverse events · maintenance of remission in Crohn's disease

It is very uncertain whether anti‐TB therapy changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Anti‐tuberculous therapy for maintenance of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 2.57 [1.45, 4.55]
4 studies · 322 participants
Very low